This Acquisition Is Icy Hot

As the Global Gains guys said on twitter yesterday, "You can say many things about sanofi-aventis (NYSE: SNY  ) buying Chattem (Nasdaq: CHTT  ) , but you can't say sanofi is getting a great price."

At $93.50 per share, sanofi is paying a hefty 34% premium on Friday's closing price. The $1.9 billion price tag works out to a P/E of about 18.5-times 2010 estimated earnings. The transaction may add to the company's earnings as early as next year, but that likely has to do with the paltry return it would have gotten keeping the cash in the bank. Buying back its own shares would have also been accretive to earnings per share.

An icy price tag notwithstanding, the acquisition is still a good move for the company. The addition of Chattem's U.S. over-the-counter presence will help sanofi convert its prescription allergy medication, Allegra, into an over-the-counter product. Similar moves have helped keep sales of Merck's (NYSE: MRK  ) Claritin and Pfizer (NYSE: PFE  ) and Johnson & Johnson's (NYSE: JNJ  ) Zyrtec going after patents expired. Sanofi could have launched on its own, but buying a company with marketing channels -- Chattem sells Gold Bond, Icy Hot, and Cortizone-10, among many others -- will give the late comer a fighting chance.

With the acquisition, sanofi joins other big pharma in using acquisitions to (further) diversify away from prescription drugs. Merck got health-care products, including Coppertone sunscreen, in its acquisition of Schering-Plough. Pfizer has been a little more spastic, having sold its consumer health division to Johnson & Johnson a few years ago, and then gotten one back in the recent acquisition of Wyeth.

Not everyone is shunning drugs though. Bristol-Myers Squibb (NYSE: BMY  ) has sold or spun off most of its non-drug assets and Eli Lilly (NYSE: LLY  ) says diversification isn't its style.

Only time will tell which of the two strategies will be the best at relieving the pain from expiring patents.

Tim Hanson, part of the Global Gains team, says the top markets may not be underneath your feet.

Investing internationally doesn't have to be scary and it can certainly be profitable. Click here to grab a 30-day trial subscription to the newsletter where you'll see all of our current picks for a global economy.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a Motley Fool Inside Value pick. Johnson & Johnson is an Income Investor selection. The Fool's disclosure policy likes to use Gold Bond to lock down coffee mugs on people's desks.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1072212, ~/Articles/ArticleHandler.aspx, 9/17/2014 12:00:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement